In part because of fear of decision regret and in part because of myopia, investors price the stocks of troubled companies too low in the short run when regression to the mean would be likely to restore most of them to good health over the long run. By the same token, companies about which recent information has indicated sharp improvement are overpriced by investors who fail to recognize that matters cannot get better and better indefinitely.
